Cutaneous Squamous Cell Carcinoma Treatment Market to Surpass US$ 16,867.06 Million by 2027
Global Cutaneous Squamous Cell Carcinoma Treatment Market, by Treatment (Surgical (Moh’s Micrographic Surgery (MMS) and Electrodessication or Curettage), Non-surgical (Chemotherapy, Topical Immune Response Modifiers, Radiotherapy, and Systemic Chemotherapy)), by Application (Hospitals, Cancer Institutes, Ambulatory Surgical Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 10,309.76 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Increasing research & development by market players to augment the market growth
Major players in the market are focused on research and development of novel drugs, which is expected to boost the market growth. For instance, in April 2019, NIPPON KAYAKU, a Japan-based CSR company and Eli Lilly and Company, a pharmaceutical company entered into licensing agreement for Necitumumab, a humanized anti EGFR monoclonal antibody in Japan. The drug, Necitumumab, received the U.S. Food & Drug Administration (FDA) approval in 2015 for the first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Global Cutaneous Squamous Cell Carcinoma Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 30.6 million infected individuals worldwide as of 21st September 2020.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in Application, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of such drugs from one place to another.
Moreover the COVID-19 pandemic has impacted the supply of raw materials and potent compounds, which are used for manufacturing drugs such as cutaneous squamous cell carcinoma treatment and this is expected to hamper the market growth in the near future.
Browse 40 Market Data Tables and 35 Figures spread through 195 Pages and in-depth TOC on “Cutaneous Squamous Cell Carcinoma Treatment Market – by Treatment (Surgical (Moh’s Micrographic Surgery (MMS) and Electrodessication or Curettage), Non-surgical (Chemotherapy, Topical Immune Response Modifiers, Radiotherapy, and Systemic Chemotherapy), by Application (Hospitals, Cancer Institutes, Ambulatory Surgical Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027”
To know the latest trends and insights prevalent in the global Cutaneous Squamous Cell Carcinoma Treatment market, click the link below:
Key players in the market are focused on researching and developing novel drugs for cutaneous squamous cell carcinoma treatment. For instance, in December 2016, Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, announced about the Phase II study of VDA-1102 ointment, a potent selective VDAC/HK2 modulator in actinic keratosis (AK). The drug candidate is being developed for first-in-class treatment for actinic keratosis, an early form of cutaneous squamous cell carcinoma (cSCC) featuring potency, safety, and tolerability at the same time.
Key Takeaways of the Global Cutaneous Squamous Cell Carcinoma Treatment Market:
- The global cutaneous squamous cell carcinoma treatment market is expected to exhibit a CAGR of 7.2% during the forecast period, owing to increasing cases of cutaneous squamous-cell carcinoma. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in February 2017, reports that non-small-cell lung cancer (NSCLC) represents approximately 80%–85% of all lung cancers, and within the NSCLC category, squamous cell histology accounts for 25%–30%.
- Among treatment, non-surgical segment held a dominant position in the cutaneous squamous cell carcinoma treatment market in 2019, owing to its effective indication for the prevention and treatment. For instance, according to the Hindawi Limited, an open access journal publishers, radiotherapy is based on the administration of ionizing radiations for skin cancer treatment through two different techniques, which includes external radiotherapy and interstitial brachytherapy (brachytherapy) that provides effective results.
- Among application, hospitals segment held a dominant position in the cutaneous squamous cell carcinoma treatment market in 2019, as hospitals are the first choice of the patients and most of the cases are registered in the hospitals and this is expected to drive the segment growth during the forecast period.
- Key players operating in the global cutaneous squamous cell carcinoma treatment market include Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others.
Contact Us